Drugs /

mg1 maraba/mage-a3

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine consisting of the attenuated, genetically-modified, oncolytic form of the Maraba virus, MG1, which has been engineered to express a gene encoding the cancer testis antigen melanoma antigen family A3 (MAGE-A3), with potential antineoplastic activity. Upon administration of genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine, the attenuated Maraba virus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective Maraba virus-mediated cytotoxicity in those cancer cells, and leads to cancer cell lysis. In addition, the expression of MAGE-A3 further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A3. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. The attenuated virus is a double mutant strain with single amino acid substitutions occurring in both G protein (Q242R) and M protein (L123W).

Clinical Trials

View Clinical Trials for mg1 maraba/mage-a3

Mg1 maraba/mage-a3 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating mg1 maraba/mage-a3, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open).

MAGEA3 Expression is the most frequent biomarker inclusion criterion for mg1 maraba/mage-a3 clinical trials.

Adenocarcinoma of the gastroesophageal junction, breast carcinoma, and esophageal carcinoma are the most common diseases being investigated in mg1 maraba/mage-a3 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mg1 Maraba/mage-A3
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Mg1 Maraba/mage-A3
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mg1 maraba/mage-a3 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mg1-magea3, genetically-modified mage-a3-expressing mg1 maraba virus vaccine, mg1ma3
NCIT ID [1]:
C118973

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.